OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]]), the Bothell, WA-based developer of cancer drugs, said today it has named Jack Goldstein as its new chairman, and H. Stewart Parker as a member of its board of directors. Current board members Dwight Winstead and Michael Martino plan to step down at the company’s upcoming annual meeting on June 8. Goldstein was president and chief operating officer of Chiron when that company was acquired by Novartis in 2006, while Parker was the founder and CEO of Seattle-based Targeted Genetics until she left the company in November 2008.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
